ASCO: Controversies in Phase I Clinical Trials

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Steve Joffe, MD discusses the ethical challenges and controversies in phase I clinical cancer trials.

Steve Joffe, MD discusses the ethical challenges and controversies in phase I clinical cancer trials: how physicians should present these clinical trials to patients-phase I trials typically have very low response rates (5% to 10%)-and explain their purpose without exaggerating the likely results.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Related Content
Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Givastomig Regimen Yields Preliminary Activity in Gastric/GEJ Cancers

Kristi Rosa
July 14th 2025
Article

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.

Real-World Data Show Activity With Ivosidenib in IDH1+ Cholangiocarcinoma

Kyle Doherty
July 11th 2025
Article

Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Data from a phase 1 trial showed an ORR of 68% and a DCR of 93% with ZL-1310 in those with extensive-stage small cell lung cancer during dose escalation.

ZL-1310 Shows Promising Activity in Pretreated R/R ES-SCLC

Tim Cortese
July 9th 2025
Article

Data from a phase 1 trial showed an ORR of 68% and a DCR of 93% with ZL-1310 in those with extensive-stage small cell lung cancer during dose escalation.

Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.

Encorafenib Combo Yields Efficacy Across BRAF V600E+ CRC Subgroups

Kristi Rosa
July 9th 2025
Article

Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.